Featured
-
-
Molecular Diagnostics
| Open AccessCharacterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma
- T Wang
- , H S Hu
- & S Q Cheng
-
-
Clinical Study
| Open AccessCapecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
- J Feliu
- , M J Safont
- & M González-Barón
-
Molecular Diagnostics
| Open AccessQuantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma
- C K Kontos
- , I N Papadopoulos
- & A Scorilas
-
Molecular Diagnostics
| Open AccessThe proportion of tumour cells is an independent predictor for survival in colorectal cancer patients
- N P West
- , M Dattani
- & H Grabsch
-
Translational Therapeutics
| Open AccessInsulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells
- Y Tomimaru
- , H Eguchi
- & H Nagano
-
Molecular Diagnostics
| Open AccessPrediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
- H Takeshita
- , D Ichikawa
- & E Otsuji
-
Genetics and Genomics
| Open AccessRelationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers
- E Rampazzo
- , R Bertorelle
- & A De Rossi
-
Epidemiology
| Open AccessPredicted vitamin D status and pancreatic cancer risk in two prospective cohort studies
- Y Bao
- , K Ng
- & C S Fuchs
-
Clinical Study
| Open AccessPrognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review
- G Peach
- , C Kim
- & P Ziprin
-
Epidemiology
| Open AccessNon-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study
- M C Bradley
- , C M Hughes
- & L J Murray
-
Letter to the Editor
| Open AccessReply to: The definition of locally advanced pancreatic cancer
- S Boeck
- & V Heinemann
-
Letter to the Editor
| Open AccessThe definition of locally advanced pancreatic cancer
- N Zanini
- , M Masetti
- & E Jovine
-
Translational Therapeutics
| Open AccessOncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
- M T de Bruijn
- , D A E Raats
- & O Kranenburg
-
Molecular Diagnostics
| Open AccessExpansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery
- D D Fang
- , Y J Kim
- & P A Moore
-
Molecular Diagnostics
| Open AccessCirculating microRNAs in plasma of patients with gastric cancers
- M Tsujiura
- , D Ichikawa
- & E Otsuji
-
Clinical Study
| Open AccessChemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
- J Northover
- , R Glynne-Jones
- & J Ledermann
-
Translational Therapeutics
| Open AccessMitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
- C Montagut
- , M Iglesias
- & J Albanell
-
Translational Therapeutics
| Open AccessFibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration
- G Sonvilla
- , S Allerstorfer
- & B Marian
-
Short Communication
| Open AccessReproductive factors and risks of biliary tract cancers and stones: a population-based study in Shanghai, China
- G Andreotti
- , L Hou
- & A W Hsing
-
Clinical Study
| Open AccessOxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
- R Zarate
- , J Rodríguez
- & J Gacía-Foncillas
-
Clinical Study
| Open AccessPreferences for colorectal cancer screening strategies: a discrete choice experiment
- L Hol
- , E W de Bekker-Grob
- & M L Essink-Bot
-
Letter to the Editor
| Open AccessImatinib plasma levels: correlation with clinical benefit in GIST patients
- N Widmer
- , L A Decosterd
- & T Buclin
-
Letter to the Editor
| Open AccessKRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
- E Lopez-Crapez
- , L Mineur
- & P-J Lamy
-
Letter to the Editor
| Open AccessLoss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
- C Mao
- , R-Y Liao
- & Q Chen
-
Letter to the Editor
| Open AccessReply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
- C Cremolini
- , A Ruzzo
- & F Loupakis
-
Genetics and Genomics
| Open AccessMutSβ exceeds MutSα in dinucleotide loop repair
- J Kantelinen
- , M Kansikas
- & M Nyström
-
Clinical Study
| Open AccessEfficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
- C-H Hsu
- , T-S Yang
- & A-L Cheng
-
Translational Therapeutics
| Open AccessActivating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
- G Smith
- , R Bounds
- & C R Wolf
-
Translational Therapeutics
| Open AccessInhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells
- O Shinto
- , M Yashiro
- & K Hirakawa
-
Molecular Diagnostics
| Open AccessFactors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer
- Y Hamaya
- , K Yoshida
- & S Kanaoka
-
Molecular Diagnostics
| Open AccessEstablishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma
- Y Kato
- , M Yashiro
- & K Hirakawa
-
Molecular Diagnostics
| Open AccessHigh expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer
- E L Wang
- , Z R Qian
- & T Sano
-
Clinical Study
| Open AccessPlasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer
- R J E Skipworth
- , D A C Deans
- & K C H Fearon
-
Translational Therapeutics
| Open AccessHuman apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers
- A Al-Attar
- , L Gossage
- & S Madhusudan
-
Molecular Diagnostics
| Open AccessExpansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease
- S Behboudi
- , A Alisa
- & R Williams
-
Translational Therapeutics
| Open AccessOverexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells
- T-Y Jeon
- , M-E Han
- & S-O Oh
-
Molecular Diagnostics
| Open AccessEarly growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells
- D Mahalingam
- , A Natoni
- & E Szegezdi
-
Clinical Study
| Open AccessDefining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status
- D J Watkins
- , I Chau
- & A Gillbanks
-
Genetics and Genomics
| Open AccessGene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases
- T Ishiguro
- , H Avila
- & D D Boyd
-
Genetics and Genomics
| Open AccessReversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor
- O Galamb
- , S Spisák
- & B Molnár
-
Molecular Diagnostics
| Open AccessOestrogen receptor-α contributes to the regulation of the hedgehog signalling pathway in ERα-positive gastric cancer
- C Kameda
- , M Nakamura
- & M Katano
-
Clinical Study
| Open AccessRandomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
- N C Tebbutt
- , M M Cummins
- & J Zalcberg
-
Clinical Study
| Open AccessCetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- F Lordick
- , B Luber
- & C Peschel
-
Clinical Study
| Open AccessPhase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- T Trarbach
- , M Moehler
- & S Kanzler
-
Molecular Diagnostics
| Open AccessRole of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-κB signalling pathways in human pancreatic adenocarcinoma cells
- S T Lau
- , Z X Lin
- & P S Leung
-
Translational Therapeutics
| Open AccessC20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
- K Yamaguchi
- , M Sakai
- & Y Furukawa
-
Molecular Diagnostics
| Open AccessConsiderations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
- C Dive
- , R A Smith
- & J P Neoptolemos
-
Clinical Study
| Open AccessPerformance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study
- G Tranø
- , W Sjursen
- & L J Vatten